Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Completed · Phase 2 · Has a placebo group

Conditions studied: Cancer, Bowel Dysfunction

In brief

Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain. Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.

Key facts

Study ID

NCT00135577

Run by

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

People needed

67

Starts

2004-09-01

Expected to finish

2007-04-01

Last updated by the study team

2015-09-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completed GSK sponsored alvimopan (opioid-induced bowel dysfunction) OBD study for subjects with cancer-related pain, e.g. SB-767905/008.
• Taking full agonist opioid therapy for cancer related pain.
• Met entry criteria of OBD in original study and per investigator continues to require therapy for management of OBD.
• Capable of completing paper questionnaires at the study visits.

You may not qualify if…

• Unable to eat or drink.
• Taking opioids for management of drug addiction.
• Unable to use only rescue laxatives provided.
• Inappropriately managed severe constipation that puts subject at risk of complications.
• Has gastrointestinal (GI) or pelvic disorder known to affect bowel transit.
• Concomitant medication(s), medical condition, or clinically significant laboratory abnormality that could jeopardize subject and also contraindicate study participation.

Where it is running

• GSK Investigational Site — Duarte, California, United States
• GSK Investigational Site — Fountain Valley, California, United States
• GSK Investigational Site — La Verne, California, United States
• GSK Investigational Site — Sacramento, California, United States
• GSK Investigational Site — San Diego, California, United States
• GSK Investigational Site — New Port Richey, Florida, United States
• GSK Investigational Site — Tampa, Florida, United States
• GSK Investigational Site — West Des Moines, Iowa, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Worcester, Massachusetts, United States
• GSK Investigational Site — St Louis, Missouri, United States
• GSK Investigational Site — Durham, North Carolina, United States
• GSK Investigational Site — Hendersonville, North Carolina, United States
• GSK Investigational Site — Tacoma, Washington, United States
• GSK Investigational Site — Winnipeg, Manitoba, Canada
• GSK Investigational Site — St. John's, Newfoundland and Labrador, Canada
• GSK Investigational Site — Greater Sudbury, Ontario, Canada
• GSK Investigational Site — Kitchener, Ontario, Canada
• GSK Investigational Site — Bonaventure, Quebec, Canada
• GSK Investigational Site — Chandler, Quebec, Canada
• GSK Investigational Site — Sherbrooke, Quebec, Canada
• GSK Investigational Site — Helsinki, Finland
• GSK Investigational Site — Bordeaux, France
• GSK Investigational Site — Strasbourg, France
• GSK Investigational Site — Vandœuvre-lès-Nancy, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.